A comparative study of preclinical and clinical molecular imaging response to EGFR inhibition using osimertinib in glioblastoma

By sjmartinez • March 7, 2025

Ellingson BM, Okobi Q, Chong R, Plawat R, Zhao E, Gafita A, Sonni I, Chun S, Filka E, Yao J, Telesca D, Li S, Li G, Lai A, Nghiemphu P, Czernin J, Nathanson DA, Cloughesy TF. A comparative study of preclinical and clinical molecular imaging response to EGFR inhibition using osimertinib in glioblastoma. Neurooncol Adv. 2025 Feb 19;7(1):vdaf022. doi: 10.1093/noajnl/vdaf022. PMID: 40051661; PMCID: PMC11883343.

Tags: Cardiology/Epi, EGFR, FDG PET, Glioblastoma, imaging biomarker, molecular imaging, Osimertinib, Publications

Metabolomics-Based Investigation of PFOS-Induced Molecular Perturbations Across Multiple Rat Organs

Yen TH, Lee SH, Liang HJ, Huang ZX, Chen CT, Li C, Lin CY. Metabolomics-Based Investigation of PFOS-Induced Molecular Perturbations Across Multiple Rat Organs. Environ[...]

Trimethylamine N-oxide and related metabolites may regulate DNA methylation and trigger cardiovascular disease

Ma J, Lai CQ, Li XS, Wang M, Wang Z, Yao J, Guo X, Taylor KD, Lee S, Tracy RP, Peter D, Liu Y, Rotter[...]

Transcatheter Pulmonary Valve Implantation With the Alterra Adaptive Prestent and SAPIEN 3 Transcatheter Heart Valve: 3-Year Pooled Outcomes of the ALTERRA Trials

Torres AJ, Dimas VV, Shahanavaz S, Balzer D, Morgan G, Lim DS, Armstrong AK, Berman D, Babaliaros V, Kim D, Gillespie MJ, Sommer R, Aboulhosn[...]